Human papillomavirus types 6 and 11 seropositivity: Risk factors and association with ano-genital warts among homosexual men
I Mary Poynten, Tim Waterboer, Fengyi Jin, David J Templeton, Garrett Prestage, Basil Donovan, Michael Pawlita, Christopher K Fairley, Suzanne M Garland, Andrew E Grulich
JOURNAL OF INFECTION | W B SAUNDERS CO LTD | Published : 2013
Awarded by National Institutes of Health, a component of the U.S. Department of Health and Human Services (NIH/NIAID/DAIDS: HVDDT)
Awarded by National Health and Medical Research Council in Australia
Awarded by NHMRC
Awarded by National Health and Medical Research Council
The Health in Men Cohort study was funded by the National Institutes of Health, a component of the U.S. Department of Health and Human Services (NIH/NIAID/DAIDS: HVDDT Award N01-AI-05395), the National Health and Medical Research Council in Australia (Project grant # 400944), and the New South Wales Health Department (Sydney). The Positive Health Cohort study was funded by the New South Wales Health Department (Sydney). The Health in Men and Positive Health Cohort studies were also funded by the Australian Government Department of Health and Ageing. Funding for HPV serology testing was from NHMRC program grant #568971 for which CKF AEG SMG .... are chief investigators. IMP (#1016307), FJ (#571402) and DJT (#1013353) are supported by Post-doctoral Training Fellowships from the National Health and Medical Research Council. The Kirby Institute (formerly NCHECR) is affiliated with the Faculty of Medicine, University of New South Wales and is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government.IMP, FJ, DJT, GP and MP have no conflicts of interest. TW is currently employed by Boehringer Ingelheim. BD has received research funding from CSL Biotherapies Ltd, and has been on the speakers' bureau for Merck and Sanofi-PasteurMSD. CKF has received honoraria and research funding from CSL Biotherapies. CKF owns shares in CSL Biotherapies the manufacturer for Gardasil and has received honoraria from Merck. SMG has received advisory board fees and grant support from CSL and GlaxoSmithKline and lecture fees from Merck, GSK and Sanofi Pasteur. SMG has received funding through her institution to conduct HPV vaccine studies for MSD and GSK, is a member of the Merck Global Advisory Board and the Merck Scientific Advisory Committee for HPV. AEG has received consulting fees and conference sponsorship from Merck, the manufacturer of the Gardasil quadrivalent HPV vaccine, and research funding, consulting fees and conference sponsorship from CSL Biotherapies, the Australian distributor of the Gardasil vaccine.